ClinicalTrials.gg
CompletedNCT07374692Updated Nov 20, 2026

Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors

An observational study in Recurrent CNS Tumors, Brain Cancer and Gliomas, sponsored by National Cancer Institute (NCI). Completed at 1 site in United States. Open to participants aged 15 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Primary conditionBrain NeoplasmsRegistry: Central Nervous System NeoplasmsReclassifiedWhy we changed it
Registry
Central Nervous System Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Brain Neoplasms
Why
  1. The study's listed conditions name Brain Neoplasms, a narrower term within Central Nervous System Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by National Cancer Institute (NCI) · Observational

How we know

Updated Sep 29, 2026Now CompletedPrimary completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
4
Ages
15 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 136 studies in Brain Neoplasms by National Cancer Institute (NCI) — 2 open to participants now, 11 under way, none of them phase 3. Brain Neoplasms · National Cancer Institute (NCI).

Enrollment
20th of 23
4 · median 76
Started
2026
the only one that year
Observational
23 of 136
none open now
Registered
136th of 136
by date

Among the 136 studies in Brain Neoplasms by National Cancer Institute (NCI), this one is the 20th largest by enrollment of the 23 observational ones that give a count, is the only one that started in 2026, is one of 23 observational ones, and was the 136th registered.

Brain Neoplasms

2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

2 of the 136 studies in Brain Neoplasms by National Cancer Institute (NCI) are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 15 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 136 studies in Brain Neoplasms by National Cancer Institute (NCI), or all of them as a file.
02

Study summary

Background:

Primary central nervous system (CNS) tumors grow in the brain and spinal cord. These tumors are rare, but they are difficult to treat and often fatal. SmartMatch is a new technology that tries to help find the best medicines for the particular tumor by testing how small pieces of surgically removed tumor tissue react to different drugs. The study team wants to see if SmartMatch can complete the analysis and generate a report within 21 days from the time of the surgery.

Objective:

To better understand CNS tumors so doctors can find better ways to treat them in the future.

Eligibility:

People aged 15 years and older with recurrent CNS tumors. Patient must already be scheduled for a surgery for the tumor at the NIH.

Design:

The study team will collect a small amount of tumor samples during the planned surgery. They may also use tumor samples from previous procedures. No new or additional procedures will be done for the purpose of this study.

The tumor samples will be sent to a lab for SmartMatch analysis. Once completed, the results will be shared with the patient and his/her local doctor. Together they can decide whether to incorporate the results into the treatment plan. It is important to know that the results may or may not be helpful.

There will only be one blood test for research. Blood and tissue samples collected may be used for additional analysis. Tumor tissue may be used to grow additional samples for further study. Participants will receive a pathology diagnosis and mutation profile generated by pathologists who specialize in CNS tumors.

The study team will seek updates on participant's health approximately every 6 months for 3 years. Tumor samples may also be collected from any additional surgery done at NIH during this time....

Read the detailed description

Background:

  • Primary central nervous system (CNS) tumors are uncommon and are mostly classified as rare diseases. Despite their low incidence, CNS cancers are associated with significant morbidity and mortality across all age groups.
  • Treatment options for CNS tumors are limited, especially upon disease progression, largely due to the incomplete understanding of disease biology and the challenges in conducting clinical studies, given the rarity of these diseases.
  • The traditional pathway for oncology drug development, involving several phases of clinical trials, can take many years to a decade and comes with a tremendously high financial cost. To overcome this challenge and speed up improving oncology patient care, drug repurposing has emerged as a useful approach.
  • Real-time drug screening for rare brain tumors is advancing precision medicine by generating clinical trial concepts aimed at overcoming key challenges in brain tumor management. However, delayed turnaround times remain a significant limitation to their clinical utility.
  • The Gujral lab at the Fred Hutchinson Cancer Center has developed SmartMatch, a cutting-edge artificial intelligence (AI)-driven system pharmacology-based platform to address the challenges in precision medicine. The platform allows the generation of drug response data using real-time tissue-based screening using freshly resected tumor or biopsy from a patient. The data collected is used to train a machine learning model, allowing precise prediction to a large panel of Food and Drug Administration (FDA)-approved drugs. This is a test that can be ordered by any physician in the US, and results are available upon request.

Objective:

-To determine the proportion of participants with advanced CNS tumors for whom SmartMatch drug screen analysis results are generated within 21 days from the time of tumor tissue acquisition

Eligibility:

  • Participants >=15 years with advanced CNS tumors.
  • Participants must have been scheduled for a brain tumor biopsy or resection planned to take place at NIH.

Design:

  • Tumor and blood samples will be collected for multi-omic analysis.
  • Fresh tumor samples will be used for drug screen analysis by SmartMatch.
  • After initial sample collection, participants will be followed remotely every 6 (+/-3) months for 3 years.
03

Conditions studied

  • Recurrent CNS Tumors
  • Brain Cancer
  • Gliomas
  • IDH-wildtype Gliomas
  • IDH-mutant Gliomas
  • Rare CNS Tumor

Browse trials for

Keywords

  • CNS Tumor
  • Brain Tumor
  • Rare Tumor
  • SmartMatch
  • Gliomas
  • Drug Screen
04

In context

Brain Neoplasms Reclassified

2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.

This study's enrollment of 4 is below the median of 99 across 433 observational studies indexed under Brain Neoplasms.

Browse Brain Neoplasms studies →

Lead sponsor

National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 335 are open to participants now.

Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.

Compared within Brain Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Central Nervous System Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
15 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study aims to collect blood and tumor samples for molecular profiling from individuals with advanced CNS tumors.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have advanced CNS tumors confirmed by a documented pathology report, including:

    • recurrent isocitrate dehydrogenase (IDH)-wild-type high-grade glioma
    • recurrent IDH-mutant gliomas
    • other recurrent CNS tumors
  • Participants must have been scheduled for a brain tumor or resection. Note: Scheduled brain tumor biopsy or resection must be at least 6 months after any previous radiation therapy, if applicable. All procedures are planned to take place at NIH.
  • Age >= 15 years.
  • Ability of participant, parent/guardian, or Legally Authorized Representative (LAR) to understand and sign a written document.

Exclusion criteria

EXCLUSION CRITERIA

None.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
4 participants (actual)

Groups and cohorts

  • 1/ IDH-wild-type

    Participants with recurrent IDH-wild type high-grade glioma

    Other: SmartMatch testing

  • 2/ IDH-mutant

    Participants with recurrent IDH-mutant gliomas

    Other: SmartMatch testing

  • 3/ Other

    Other recurrent CNS tumors

    Other: SmartMatch testing

Interventions

  • OtherSmartMatch testing

    Fresh tumor samples will be collected for the study only if available following a planned biopsy or resection performed at NIH.

07

What researchers measure

Primary outcomes

  1. To determine the proportion of participants with advanced CNS tumors for whom SmartMatch drug screen analysis results are generated within 21 days from the time of tumor tissue acquisition

    Point estimates and 95% exact confidence intervals will be calculated using the Clopper-Pearson method

    Time frame: 21 days from the time of tumor tissue acquisition

Secondary outcomes

  1. To perform molecular profiling of advanced CNS tumors at disease progression.

    Descriptive statistics will be used to summarize the molecular profiling results

    Time frame: End of Study

08

Study locations

1 site
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
09

References and documents

Publications

  • Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019. Neuro Oncol. 2022 Oct 5;24(Suppl 5):v1-v95. doi: 10.1093/neuonc/noac202. PubMed 36196752 ↗
  • Aldape K, Brindle KM, Chesler L, Chopra R, Gajjar A, Gilbert MR, Gottardo N, Gutmann DH, Hargrave D, Holland EC, Jones DTW, Joyce JA, Kearns P, Kieran MW, Mellinghoff IK, Merchant M, Pfister SM, Pollard SM, Ramaswamy V, Rich JN, Robinson GW, Rowitch DH, Sampson JH, Taylor MD, Workman P, Gilbertson RJ. Challenges to curing primary brain tumours. Nat Rev Clin Oncol. 2019 Aug;16(8):509-520. doi: 10.1038/s41571-019-0177-5. PubMed 30733593 ↗
  • Nishida-Aoki N, Bondesson AJ, Gujral TS. Measuring Real-time Drug Response in Organotypic Tumor Tissue Slices. J Vis Exp. 2020 May 2;(159). doi: 10.3791/61036. PubMed 32420994 ↗

Individual participant data

Plan to share: Yes — This study will comply with the NIH Data Management and Sharing (DMS) Policy, which applies to all new and ongoing NIH-funded research in the IRP, as of January 25, 2023, that is associated with a ZIA, with a clinical protocol that undergoes scientific review and/or will involve genomic data sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be made available as soon as possible or at the time of associated publication. Data not published in a manuscript will be shared via public source once the data set completes QC.

Access criteria: Clinical data will be made available upon request and with the permission of the study PI. Genomic data are made available via dbGAP through requests to the data custodians.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2026 to primary completion in Sep 2026, 7 months.

Of 182 non-industry observational studies under Brain Neoplasms, half reached primary completion within 82 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 269. This study's 7 months is below that.

Counting every sponsor, half of 200 studies reached it within 82 months; a quarter within 41 and three quarters within 269.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: primary completion Dec 2030 → Sep 2026 and completion Dec 2030 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2026
First posted
Jan 29, 2026
StartActual
Feb 4, 2026
Primary completionActual
Sep 10, 2026was Dec 2030
CompletionActual
Sep 10, 2026was Dec 2030
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Sep 29, 2026
Primary completion
Dec 30, 2030→Sep 10, 2026 (actual)
Sep 29, 2026
Study completion
Dec 30, 2030→Sep 10, 2026 (actual)
Sep 29, 2026
Enrollment
80 (estimated)→4 (actual)
Sep 29, 2026
Eligibility
Revised
Sep 29, 2026
Interventions
Changed Tumor sample collection→SmartMatch testing. Arms added: 1/ IDH-wild-type·2/ IDH-mutant·3/ Other; arms removed: 1/SmartMatch testing
Sep 29, 2026
Design
Study type Interventional→Observational
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Recruiting→Completed
    Primary completion Dec 30, 2030→Sep 10, 2026 (now actual)
    Study completion Dec 30, 2030→Sep 10, 2026 (now actual)
    Enrollment 80 (estimated)→4 (actual)
    Eligibility Revised
    Interventions Changed Tumor sample collection→SmartMatch testing. Arms added: 1/ IDH-wild-type·2/ IDH-mutant·3/ Other; arms removed: 1/SmartMatch testing
    Design Study type Interventional→Observational
    + 4 other changes: verification date, contact details, site details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07374692
Responsible party
Sponsor
First posted
Jan 29, 2026
Start date
Feb 4, 2026
Primary completion
Sep 10, 2026
Completion
Sep 10, 2026
Last update
Nov 20, 2026

Study contacts

Jing Wu, M.D.
principal investigator · National Cancer Institute (NCI)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion